Search the Newsreel

Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) Deal - Has The Bull Case Changed?

In early August 2026, BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors, alongside a regional licensing deal granting BeOne exclusive development and commercialization rights in select Asian markets and responsibility for …

Earnings Flash (EVOK.L) Evoke PLC Posts H1 Loss GBX-15.6

REG - Evoke PLC - H1 2026 Interim Results

Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Revolution Medicines (RVMD) just entered a comprehensive partnership with BeOne Medicines that combines joint clinical development work and a regional rights deal in …

William Blair Investment Management (RVLV) discloses 5.6% Revolve Group ownership

William Blair Investment Management, LLC has reported a 5.6% beneficial ownership stake in Revolve Group, Inc. (RVLV), as detailed in a Schedule 13G filing. As of June 30, 2026, the firm beneficially owned 2,333,717 shares, with sole voting power over 1,820,565 shares and sole …

Devon Energy (DVN) Q2 2026 Earnings Call Transcript

Key Points Interested in Devon Energy Corporation? Here are five stocks we like better. Devon exceeded Q2 guidance, generating $1.7 billion in adjusted free cash flow while beating targets for oil production, total production, operating costs and capital spending. The company tightened its 2026 …

Revolve (RVLV) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS SVP of Investor Relations - Erik Randerson Co-Founder and Co-CEO - Mike Karanikolas Co-Founder and Co-CEO - Michael Mente Chief Financial Officer - Jesse Timmermans Full Conference Call …

Evolv Technologies Q2 Earnings Call Highlights

Key Points Interested in Evolv Technologies Holdings, Inc.? Here are five stocks we like better. Evolv Technologies reported strong second-quarter results, with revenue up 34% year over year to $43.8 million, ARR reaching $132.7 million, and adjusted EBITDA more than doubling to $4.4 million. …

Evolv Technologies Holdings, Inc. (EVLV) Reports Q2 Loss, Tops Revenue Estimates

Evolv Technologies Holdings, Inc. (EVLV) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items. …

Evolv Technologies (EVLV) boosts revenue while cutting net loss and generating cash

Evolv Technologies (EVLV) reported a significant increase in revenue and a narrower net loss for the first half of 2026, driven by growth in subscription and product sales. The company generated positive operating cash flow and maintains solid liquidity, with substantial remaining performance obligations …

Evolv Technology (NASDAQ: EVLV) lifts 2026 guidance after strong Q2

Evolv Technology reported strong Q2 2026 results, with revenue up 34% year-over-year to $43.8 million and Annual Recurring Revenue (ARR) reaching $132.7 million. The company narrowed its net loss and improved Adjusted EBITDA, leading to a raised 2026 guidance. Evolv now anticipates total revenue …

Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach?

Revolution Medicines (NASDAQ:RVMD) just picked up a partner with deep pockets and a presence across Asia. On August 10, the company announced a multi-part collaboration with BeOne Medicines, pairing clinical development with a regional rights deal. For a stock that has already climbed more …

EVOLV TECHNOLOGIES ($EVLV) Releases Q2 2026 Earnings, Stock Rises

Evotec SE (EVO) Stock Analysis: Exploring An 84% Potential Upside For Strategic Investors

Evotec SE (EVO), a German drug manufacturing company, presents a compelling investment opportunity despite current unprofitability and revenue decline. Analysts project an 84.27% potential upside, driven by strategic collaborations with major institutions and ongoing innovation in drug discovery. The stock is technically oversold, suggesting …

Gevo, Inc. (GEVO) Options Chain

This article provides detailed options chain data for Gevo, Inc. (GEVO), including calls and puts expiring on August 21, 2026. It lists strike prices, last trade dates, prices, bid/ask spreads, volume, open interest, and implied volatility for various contracts. The stock was trading at …

Devon Energy Corp (DVN) Aktienanalyse & Prognose

Denver company leaves South Dakota, records $176 million charge

Gevo, a Denver-based company, is pulling out of South Dakota, where it had planned its flagship facility and received significant tax incentives. This departure has resulted in the company recording a $176 million impairment charge. The article suggests this is a major development for …

BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies

BeOne Medicines and Revolution Medicines have announced a multi-part collaboration to evaluate drug combinations for RAS-addicted cancers and extend the geographic footprint of Revolution Medicines' therapies. The deal includes a clinical collaboration for combination studies using BeOne's oncology assets and Revolution's four RAS(ON) inhibitors, …

HC Wainwright Issues Negative Estimate for Evommune Earnings

HC Wainwright has significantly lowered its earnings per share estimates for Evommune (NYSE:EVMN) for Q3 2026 and the full fiscal year 2026, forecasting a larger loss. This comes after Evommune missed its consensus earnings estimate for the last quarter. The analyst community shows mixed …

Leon Recanati Discloses Investment at Evogene Ltd. with 5.7% Stake

Leon Recanati has disclosed a 5.7% stake in Evogene Ltd., acquiring 800,000 shares for approximately $400,000. This investment comes ahead of a contested director election at Evogene’s upcoming annual meeting on September 4, 2026. Recanati intends to support the current board of directors, citing …

Evogene (EVGN) director Leon Recanati buys 800,000 shares, lifts stake to 5.7%

Evogene director Leon Recanati has increased his stake in the company to 5.7% by purchasing 800,000 ordinary shares for approximately $400,000. This acquisition brings his total beneficial ownership to 894,836 shares and confirms his intention to vote in favor of the current board's director …

Q3 Earnings Estimate for Gevo Issued By Northland Securities

Northland Securities has increased its Q3 2026 EPS estimate for Gevo (NASDAQ:GEVO) to $0.05 from $0.01, with a breakeven forecast for Q4 2026, though the full-year consensus remains a $0.07 per share loss. Gevo recently reported a narrower-than-expected loss of $0.01 per share and …

Evotec SE expected to post a loss of 9 cents a share - Earnings Preview

Evotec SE is projected to report a loss of 9 cents per share, according to this earnings preview. The article, sourced from Reuters via TradingView News, provides an outlook on the company's financial performance.

Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High - Should You Buy?

Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD

Bank of America Corp DE reduced its stake in Revolution Medicines, Inc. by 30.2% in Q1 2026, selling 265,688 shares and retaining 614,157 shares valued at $59.7 million. Despite this, institutional investors own 94.34% of the company, and Wall Street analysts generally maintain a …

Evolv Technologies (EVLV) Earnings Date and Reports 2026

Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus

Revolution Medicines (RVMD) recently announced a collaboration with BeOne Medicines, impacting its stock valuation. While analysts set a consensus price target slightly below the current share price at $204.38, Simply Wall St's DCF model suggests a deep undervaluation at $721.01. The article highlights the …

Gevo cancels plans for South Dakota SAF plant, focuses on North Dakota projects

Gevo has canceled its plans for a sustainable aviation fuel (SAF) production facility in Lake Preston, South Dakota, citing rising capital costs and construction expenses. The company will instead focus its efforts on developing two existing SAF projects in North Dakota. This strategic shift …

Evolent Health, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:EVH) 2026-08-10

Key Points Interested in Evolent Health, Inc? Here are five stocks we like better. Evolent raised its 2026 outlook after Q2 revenue rose 31% sequentially to $653 million and adjusted EBITDA increased 27% to $28 million. Full-year revenue guidance is now $2.6 billion–$2.7 billion, …

Fund Update: 4,446,509 DEVON ENERGY (DVN) shares added to KING LUTHER CAPITAL MANAGEMENT CORP portfolio

KING LUTHER CAPITAL MANAGEMENT CORP has significantly increased its stake in DEVON ENERGY (DVN) by adding over 4.4 million shares to its portfolio, as reported in a new SEC 13F filing for the Q2 2026 period. This move is part of broader institutional activity …

Gevo Abandons ATJ-60 SAF Project, Pivots to North Dakota

Gevo Inc., an American renewable fuels producer, has canceled its ATJ-60 sustainable aviation fuel project in Lake Preston, South Dakota, citing an unfavorable regulatory environment regarding CO2 transport infrastructure. The project's viability was undermined by changes in state law and the South Dakota Public …

Evolution Metals Appoints Kenji Konishi as Head of Magnet Engineering Production

Evolution Metals & Technologies Corp. announced the appointment of Kenji Konishi as Head of Magnet Engineering Production, as disclosed in a Form 8-K filing on August 10, 2026. This appointment was also communicated via a press release issued on the same day.

Revolution Medicines, Inc. (RVMDW) Stock Price, News, Quote & History

Devon Energy Gains as Oil Strength and Earnings Positioning Lift Shares

BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia

BeOne Medicines and Revolution Medicines have formed a two-part partnership concerning RAS(ON) inhibitors in select Asian markets. The agreement includes clinical combination studies and regional commercialization rights for Revolution Medicines' four clinical-stage RAS(ON) inhibitors. BeOne will also fund and conduct a global registrational Phase …

Evotec (NASDAQ:EVO) Shares Gap Up - Here's What Happened

Evotec (NASDAQ:EVO) shares gapped up before the market opened, opening at $2.10 after closing at $2.00, and last traded at $2.0950 on modest volume. Analyst sentiment for the Germany-based biotechnology company is mixed, with a consensus "Hold" rating and a $3.00 average price target, …